Partex and Sanofi are expanding their collaboration, leveraging Partex’s AI subsidiary, Innoplexus, to identify new uses for Sanofi’s out-licensing portfolio. The partnership aims to discover new opportunities through detailed analysis and lab validation studies. Innoplexus will play a key role in examining and enhancing various out-licensing asset candidates across different therapeutic areas, with the ultimate goal of repurposing these assets to meet patient needs.

Gunjan Bhardwaj, CEO of Partex, commented, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery. By harnessing the power of AI, we aspire to unlock the hidden potential within Sanofi's out-licensing portfolio and bring hope to patients suffering from unmet medical needs. This collaboration is a testament to our shared commitment to advancing healthcare through cutting-edge technology.”

The collaboration is already in motion, with the selection of the first three assets for AI predictions, set to be completed in 2024. Partex will receive an upfront cash component at the start of the collaboration and an opportunity to receive additional future financial incentives.